These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 9645802)

  • 1. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
    Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
    Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.
    Otto MG; Mayer AD; Clavien PA; Cavallari A; Gunawardena KA; Mueller EA
    Transplantation; 1998 Dec; 66(12):1632-40. PubMed ID: 9884251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P; Niese D
    Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. NOVARTIS OLN-353 Study Group.
    Brennan DC; Barbeito R; Burke J; Brayman K; Greenstein S; Chang T
    Kidney Int; 1999 Aug; 56(2):685-91. PubMed ID: 10432409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral.
    Pasha TM; Wiesner RH; Dahlke LM; Porayko MK; Krom RA
    Liver Transpl Surg; 1998 Sep; 4(5):410-5. PubMed ID: 9724479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
    Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
    Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoral use in the cardiac transplant recipient.
    Valantine H
    Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation.
    Alvarez F; Atkison PR; Grant DR; Guilbault N; Jones AB; Kim PS; Kneteman NM; Laurin L; Martin SR; Murphy GF; Paradis K; Shapiro J; Smith LJ; Superina RA
    Transplantation; 2000 Jan; 69(1):87-92. PubMed ID: 10653385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.
    Graziadei IW; Wiesner RH; Marotta PJ; Porayko MK; Dahlke LJ; Wilson SM; Steers JL; Krom RA
    Transplantation; 1997 Sep; 64(5):726-31. PubMed ID: 9311710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
    Taesch S; Niese D
    Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
    Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
    Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
    Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients].
    Sperschneider H; Wagner C; Korn A; Christians U
    Med Klin (Munich); 1997 Oct; 92(10):589-96. PubMed ID: 9446006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.
    Mueller EA; Kovarik JM; van Bree JB; Lison AE; Kutz K
    Transplantation; 1994 Apr; 57(8):1178-82. PubMed ID: 8178343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
    Offermann G; Korn A
    Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors.
    Akhlaghi F; Keogh AM; McLachlan AJ; Kaan A
    J Heart Lung Transplant; 2001 Apr; 20(4):431-8. PubMed ID: 11295581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.
    Chu SH; Pang ST; Chiang YJ; Chuang CK; Chen HW; Chen CS; Chou CC; Huang CC
    Transplant Proc; 1998 Nov; 30(7):3521-3. PubMed ID: 9838543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.